Home » Stocks » Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc. (CATB)

Stock Price: $6.70 USD 0.09 (1.36%)
Updated Aug 12, 2020 10:29 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 127.84M
Revenue (ttm) n/a
Net Income (ttm) -30.58M
Shares Out 19.08M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $6.70
Previous Close $6.61
Change ($) 0.09
Change (%) 1.36%
Day's Open 6.65
Day's Range 6.54 - 6.82
Day's Volume 30,145
52-Week Range 2.74 - 7.73

More Stats

Market Cap 127.84M
Enterprise Value 75.32M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.08M
Float 16.95M
EPS (basic) -2.14
EPS (diluted) -2.21
FCF / Share -1.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 763,029
Short Ratio 4.96
Short % of Float 4.90%
Beta 1.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.21
Revenue n/a
Operating Income -31.02M
Net Income -30.58M
Free Cash Flow -28.73M
Net Cash 52.52M
Net Cash / Share 2.75
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -31.67%
ROE -54.46%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$37.50*
(459.70% upside)
Low
15.0
Current: $6.70
High
60.0
Target: 37.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue--0.50----
Gross Profit--0.50----
Operating Income-27.09-26.37-27.09-35.56-31.66-21.68-18.12
Net Income-26.29-25.87-27.36-36.06-32.63-21.88-18.12
Shares Outstanding11.205.052.171.620.800.040.04
Earnings Per Share-2.35-5.12-12.62-22.20-40.60-515.60-478.00
Operating Cash Flow-26.57-23.47-26.84-32.86-29.79-20.41-16.37
Capital Expenditures-0.010.37-0.03-0.41-0.42-0.23-0.04
Free Cash Flow-26.58-23.10-26.86-33.27-30.21-20.64-16.41
Cash & Equivalents36.2437.5716.4838.6462.8914.7830.59
Total Debt2.25-2.485.728.894.75-
Net Cash / Debt33.9937.5714.0032.9254.0010.0330.59
Assets41.7839.1717.9040.2164.1715.9631.00
Liabilities6.064.236.1111.1213.688.8783.19
Book Value35.7234.9411.7929.0950.49-73.05-52.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catabasis Pharmaceuticals, Inc.
Country United States
Employees 27
CEO Jill C. Milne

Stock Information

Ticker Symbol CATB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CATB
IPO Date June 25, 2015

Description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company also has a preclinical research collaboration with the Jain Foundation to study edasalonexent (CAT-1004) in Dysferlinopathy. The company was founded in 2008 and is based in Cambridge, Massachusetts.